BRII BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.16 HKD | +6.42% |
|
+11.54% | -49.12% |
| 03-25 | Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024 | |
| 03-22 | Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
ETFs positioned on Brii Biosciences Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.53% | 4 M€ | -27.92% | ||
| 0.00% | 4 M€ | -4.41% | - |
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Companyâs products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.
Calendar
2024-06-24
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.074
CNY
Average target price
4.303
CNY
Spread / Average Target
+300.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -49.12% | 108M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2137 Stock
- Funds and ETFs Brii Biosciences Limited
